Skip to content
Companies

MiNDERA

Skin patch test that predicts psoriasis drug response

Raised to date

$55.9M

of $78.4M offered across 2 Form D filings

Still open
$22.5M
Investors
25
Last filed
Jul 28, 2026

About

Mindera Health is a precision-medicine diagnostics company in Vista, California that reads the skin transcriptome without a surgical biopsy. Its penny-sized dermal biomarker patch extracts thousands of RNA transcripts in about five minutes, and machine learning models on that data predict which therapies a patient is likely to respond to. Its lead test, Mind.Px, measures roughly 100 mRNA biomarkers to predict a psoriasis patient's response to specific biologic drugs. The company runs a CLIA-certified, CAP-accredited laboratory in the San Diego area.

Replaces the punch biopsy with an adhesive patch that captures the skin transcriptome painlessly in five minutes, then pairs it with machine learning to predict biologic drug response before an expensive therapy is prescribed.

Funding

$50M round, first sold Jul 2026$30.4M sold$19.6M still open202420252026
Now
  • EquityFiled Jul 28, 2026Form D
    $30.4M/ $50M
  • DebtFiled Apr 1, 2026Form D/A
    $25.4M/ $28.4M

Product

Mind.Px

Molecular diagnostic test

A non-invasive predictive diagnostic test for psoriasis. A dermal biomarker patch collects skin RNA in about five minutes, and Mindera's laboratory and machine learning models assess roughly 100 mRNA biomarkers to determine which biologic therapy a patient is likely to respond to.

  • Penny-sized dermal biomarker patch, painless and applied in about five minutes
  • Extracts thousands of RNA transcripts from the skin without a punch biopsy
  • Assesses roughly 100 mRNA biomarkers predictive of biologic drug response

Built for

Dermatologists and dermatology practices treating moderate-to-severe psoriasis, along with the patients and payers covering biologic therapy

People on file